Latest Breaking News On - Anticancer ruthenium compound - Page 1 : comparemela.com

/PRNewswire/ Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that will be presenting research supporting the use of BOLD-100 in.

South koreaBritish columbiaMark bazettWalter bergerPreclinical development at bold therapeuticsBold therapeutics incUniversity of viennaSmall molecule therapeutic agentsMedical universityAnticancer ruthenium compoundMetabolic vulnerabilityPreclinical developmentBold therapeuticsBold therapeutics inc